HIV drug resistance: brief report 2024
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents
Drugs
-
Deciphering diseases and biological targets for environmental chemicals using toxicogenomics networks
Exposure to environmental chemicals and drugs may have a negative effect on human health. An essential step towards understanding the effect of chemicals on human health is to identify all possible molecular targets of a given chemical. Recently, various network-oriented chemical pharmacology approaches have been published.
-
In Court
Canada refuses Sumas:The federal court of Canada ruled out the possibility of establishing a US-based power plant near the Canadian border. The company, Sumas Energy 2, proposed to source natural gas
-
Winds of changes
Indian industrialists and scientists want the country"s property rights to be "strengthened", but the powerful drugs industry wants to maintain the status quo
-
How images can break or make corporations
HOW IMPORTANT is a chief executive's personality in the way a corporation works? Very, says Matthew Lynn in this book. In a game with billions at stake, it is a rare breed of people who have the
-
Foetal tissue can cure terminal diseases
Tissue taken from aborted foetuses and implanted into the bodies of patients suffering from several incurable diseases has shown encouraging results
-
Come together
Delving into the underworld of matter, scientists are coming up with miniaturised miracles
-
Big bite
As the malaria parasite and its mosquito carrier become increasingly immune to pesticides and drugs, a recourse to vaccines seems to be the only option
-
Untamed bacteria
UK s efforts to control antibiotic resistant bacteria fails
-
Vector cells
A patient's own cells could be used to carry vital drugs to diseased organs. Researchers in Ireland are developing a device, which loads red blood cells with a drug, then injects the cells back into
-
Tonic for the industry, trial for the patients
Industry pundits predict that greater decentralisation for the drug sector will raise production to three times the present level in less than a decade. Higher costs will, of course, be the price the common person will have to pay